ClinicalTrials.gg
CompletedNCT04707391Updated Jul 3, 2024Results posted

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

A Phase 3 interventional study of MenABCWY vaccine and Placebo in Meningitis, Meningococcal, sponsored by GlaxoSmithKline. Completed at 69 sites in 4 countries. Open to participants aged 15 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,250
Allocation
Randomized
Ages
15 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Meningitis, Meningococcal with a site in United States — none open to participants now, 1 under way, none of them phase 3. Meningitis, Meningococcal · United States.

Enrollment
9th of 33
1,250 · median 751
Started
2021
with 1 other
Phase 3
16 of 36
none open now
Registered
35th of 36
by date
Lead sponsor
4 of 36
GlaxoSmithKline

Among the 36 studies in Meningitis, Meningococcal with a site in United States, this one is the 9th largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2021, is one of 16 in phase 3, and was the 35th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

None of the 36 studies in Meningitis, Meningococcal with a site in United States is open now. The open studies under Meningitis, Meningococcal, anywhere →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 15 Years to 25 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies in Meningitis, Meningococcal with a site in United States as a file.
02

Study summary

The purpose of this study was to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine.

03

Conditions studied

  • Meningitis, Meningococcal

Keywords

  • Neisseria meningitidis
  • Meningococcal disease
04

Who can participate

Ages eligible
15 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants and/or participants' parents/LARs, who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow-up visits).
  2. Written or witnessed/thumb printed obtained from the participant/participant's parent(s)/LAR(s) of the participant prior to performance of any study specific procedure.
  3. Written or witnessed/thumb printed informed assent obtained from participants below the legal age of consent prior to performance of any study specific procedure.
  4. Previous vaccination with 1 dose of MenACWY vaccine at an age of 10 years or older, with an interval of at least 4 years between the previous MenACWY vaccine and enrollment (informed consent and assent [as applicable]) into this study.
  5. A male or female between, and including, 15 and 25 years of age (i.e., 25 years and 364 days) at the time of the first vaccination.
  6. Healthy participants as established by medical history, physical examination, and clinical judgment of the investigator before entering into the study.
  7. Female participants of non- may be enrolled in the study. Non childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy, or .
  8. Female participants of childbearing potential may be enrolled in the study, if the participant:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test* on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire intervention period and for 30 days after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  1. Current or previous, confirmed or suspected disease caused by N. meningitidis.
  2. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection within 60 days of enrollment.
  3. History of any reaction or likely to be exacerbated by any component of the vaccine(s)/product.
  4. Hypersensitivity, including allergy, to any component of vaccines, including diphtheria toxoid (CRM 197) and latex medicinal products or medical equipment whose use is foreseen in this study.
  5. Progressive, unstable or uncontrolled clinical conditions
  6. Clinical conditions representing a to intramuscular vaccination and blood draws.
  7. Abnormal function or modification of the immune system resulting from:

    • disorders (including, but not limited to: blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders; lupus erythematosus and associated conditions; rheumatoid arthritis and associated conditions; scleroderma and associated disorders) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes).
    • Systemic administration of (oral/intravenous/intramuscular) for more than 14 consecutive days within 90 days prior to study vaccination until the following post vaccination blood sample. This will mean prednisone ≥20 mg/day (for adult participants and ≥0.5 mg/kg/day with maximum ≥20 mg/day for pediatric participants. Inhaled and topical steroids are allowed.
    • Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination.
    • Administration of long-acting immune-modifying drugs at any time during the study period (e.g., infliximab).
  8. Any neuroinflammatory (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital neurological conditions, encephalopathies, seizures (including all subtypes such as: absence seizures, generalized tonic-clonic seizures, partial complex seizures, partial simple seizures). History of febrile convulsions should not lead to exclusion.
  9. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
  10. Use of any or non-registered product (drug, vaccine, or medical device) other than the study vaccine(s)/product during the period beginning 30 days before the first dose of study vaccine(s)/product (Day -29 to Day 1), or planned use during the study period.
  11. Previous vaccination against any group B meningococcal vaccine at any time prior to and assent as applicable (according to the participant's age).
  12. Previous vaccination with 2 or more doses of MenACWY vaccine.
  13. Administration/planned administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before any dose of study vaccine(s)/product until the following post-vaccination blood sample.
  14. Chronic administration (defined as more than 14 days in total) of or other immune-modifying drugs during the period starting 3 months prior to any vaccine/product dose until the following post-vaccination blood sample. For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants and ≥0.5 mg/kg/day with maximum ≥20 mg/day for pediatric participants. Inhaled and topical steroids are allowed.
  15. Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non investigational vaccine/product (drug or medical device).
  16. Child in care.
  17. Pregnant or lactating female.
  18. Female planning to become pregnant or planning to discontinue precautions.
  19. History of/current chronic alcohol and/or drug abuse.
  20. Involvement in the study as a study staff member or being immediate dependents, family, or household member of a study staff member.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,250 participants (actual)

Study arms

  • Experimental
    ABCWY Group

    Participants received 2 doses of the MenABCWY vaccine on Day 1 and Day 181 (0,6-month schedule) and 1 dose of placebo on Day 211.

    Combination Product: MenABCWY vaccine · Combination Product: Placebo

  • Active comparator
    ACWY Group

    Participants received 1 dose of MenACWY vaccine on Day 1 and 2 doses of MenB vaccine on Day 181 and Day 211.

    Biological: MenACWY vaccine · Combination Product: MenB vaccine

Interventions

  • Combination productMenABCWY vaccine

    2 doses of MenABCWY vaccine administered intramuscularly on Day 1 and Day 181 to participants in ABCWY group.

  • Combination productPlacebo

    1 dose of placebo administered intramuscularly on Day 211 to participants in ABCWY group

  • BiologicalMenACWY vaccine

    1 dose of MenACWY vaccine administered intramuscularly on Day 1 to participants in ACWY group

    Also known as: Menveo

  • Combination product4CMenB vaccineStudies of 4CMenB vaccine4CMenB vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2 doses of MenB vaccine administered intramuscularly on Day 181 and Day 211 to participants in ACWY group. MenB vaccine is a non-investigational medical product (NIMP) in this study and is administered only in compliance with standard of care.

    Also known as: Bexsero

06

What researchers measure

Primary outcomes

  1. Percentages of Participants With a 4-fold Rise in Human Serum Bactericidal Assay (hSBA) Titers Against N. Meningitidis Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination and the Single MenACWY Vaccination, Relative to Baseline

    Four-fold rise is defined as: - a post-vaccination hSBA titer equal to or higher than (\>=) 16 for participants with a pre-vaccination hSBA titer \<4; - a post-vaccination hSBA titer \>= 4 times the LLOQ for participants with a pre vaccination hSBA titer \>= limit of detection (LOD) but \< LLOQ; and - a post-vaccination hSBA titer \>= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer \>= LLOQ.

    Time frame: At 1 month after vaccination schedule (i.e., Day 211 for ABCWY group and Day 31 for ACWY group) compared to Day 1 (Baseline)

  2. Percentages of Participants With a 4-fold Rise in hSBA Titers Against N. Meningitidis Serogroups A, C, W, and Y at 1 Month After the First MenABCWY Vaccination and the Single MenACWY Vaccination, Relative to Baseline

    Four-fold rise is defined as: - a post-vaccination hSBA titer equal to or higher than (\>=) 16 for participants with a pre-vaccination hSBA titer \<4; - a post-vaccination hSBA titer \>= 4 times the LLOQ for participants with a pre vaccination hSBA titer \>= limit of detection (LOD) but \< LLOQ; and - a post-vaccination hSBA titer \>= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer \>= LLOQ.

    Time frame: At 1 month after the first vaccination (i.e., Day 31) compared to Day 1 (Baseline)

  3. Number of Participants With Solicited Administration Site Events Following Vaccination at Day 1 for ABCWY Group and ACWY Group

    Assessed solicited administration site events include injection site pain, erythema, swelling, induration. Any pain = occurrence of the symptom regardless of intensity grade and any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.

    Time frame: During the 7 days (including day of vaccination) following vaccination at day 1 for ABCWY group and ACWY group

  4. Number of Participants With Solicited Administration Site Events Following Vaccination at Day 181 for ABCWY Group

    Assessed solicited administration site events include injection site pain, erythema, swelling, induration. Any pain = occurrence of the symptom regardless of intensity grade and any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.

    Time frame: During the 7 days (including day of vaccination) following vaccination at Day 181 for ABCWY group

  5. Number of Participants With Solicited Systemic Events Following Vaccination at Day 1 for the ABCWY Group and ACWY Group

    Assessed solicited systemic events include fever \[body temperature \>= 38.0°C (celsius) /100.4°F (Fahrenheit)\], nausea, fatigue, myalgia, arthralgia, headache.

    Time frame: During the 7 days (including day of vaccination) following vaccination at day 1 for the ABCWY group and ACWY group

  6. Number of Participants With Solicited Systemic Events Following Vaccination at Day 181 for the ABCWY Group

    Assessed solicited systemic events include fever \[body temperature \>= 38.0°C/100.4°F\], nausea, fatigue, myalgia, arthralgia, headache.

    Time frame: During the 7 days (including day of vaccination) following vaccination at day 181 for the ABCWY group

  7. Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs)

    Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it. An MAE is defined as an unsolicited AE for which the participant received medical attention such as hospitalization, or an emergency room visit, or visit to/by a health care provider.

    Time frame: During the 30 days (including day of vaccination) following vaccination at day 1 for ABCWY group and ACWY group

  8. Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs) Following Vaccination at Day 181 for ABCWY Group

    Any AE-untoward medical occurrence in a patient/clinical investigation participant, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it.

    Time frame: During the 30 days (including day of vaccination) following vaccination at day 181 for ABCWY group

  9. Number of Participants With SAEs, AEs Leading to Withdrawal, AESIs and Medically Attended AEs

    SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were assessed throughout the study period are reported in this outcome measure.

    Time frame: From Day 1 to Day 361 (throughout the study period)

Secondary outcomes

  1. Percentages of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Serogroups A, C, W, and Y at Day 1, 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination

    The immune response to MenABCWY vaccine after the first dose and single dose of MenACWY vaccine was evaluated by measuring the percentage of participants with hSBA titers \>= LLOQ against each of the serogroups A, C, W and Y.

    Time frame: At Day 1 (pre-vaccination) and 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group)

  2. Percentages of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination

    The immune response to MenABCWY vaccine after the second dose was evaluated by measuring the percentage of participants with hSBA titers \>= LLOQ against each of the serogroups A, C, W and Y.

    Time frame: 1 month after the vaccination schedule (i.e., Day 211 for ABCWY group [second dose])

  3. hSBA Geometric Mean Titers (GMTs) Against Serogroups A, C, W, and Y at Day 1, 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination

    The immune response to MenABCWY after first dose and single dose of MenACWY vaccine was evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their associated 2-sided 95% confidence intervals were calculated.

    Time frame: At Day 1 and 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group)

  4. hSBA Geometric Mean Titers (GMTs) Against Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination

    The immune response to MenABCWY after second dose was evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their associated 2-sided 95% confidence intervals were calculated.

    Time frame: 1 month after the vaccination schedule (i.e., Day 211 for ABCWY group [second dose])

  5. Geometric Mean Ratios (GMRs) Against Serogroups A, C, W, and Y at 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination

    The immune response to MenABCWY vaccine after first and single dose of MenACWY vaccine are evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.

    Time frame: At 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group) compared to baseline (Day 1)

  6. Geometric Mean Ratios (GMRs) Against Serogroups A, C, W, and Y at 1 Month After Second MenABCWY Vaccination

    The immune response to MenABCWY vaccine after second dose are evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.

    Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for ABCWY group [second dose]) compared to baseline (Day 1)

  7. Percentages of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After the Second Dose of MenABCWY Vaccination

    The immune response to MenABCWY vaccine after second dose was evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively).

    Time frame: At Day 1 and at Day 211

  8. Percentages of Participants With 4-fold Rise in hSBA Titers Against Each N. Meningitidis Serogroup B Indicator Strains at 1 Month After the Second MenABCWY Vaccination

    The immune response to MenABCWY after second dose is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). compared to baseline (day 1) in terms of 4-fold rise in hSBA titers. For each of the serogroup B indicator strains, the 4-fold rise is defined as: a post-vaccination hSBA titer \>=16 for participants with a pre-vaccination hSBA titer \<4; . a post-vaccination hSBA titer \>= 4 times the LLOQ for participants with a prevaccination hSBA titer \>= limit of detection (LOD) but \< LLOQ; and, a post-vaccination hSBA titer \>= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer \>= LLOQ.

    Time frame: At Day 211 compared to baseline (Day 1)

  9. GMTs Against Each Serogroup B Indicator Strains at Day 1 and at 1 Month After Second MenABCWY Vaccination

    The immune response to MenABCWY vaccine after the second dose was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively) in terms of GMTs at baseline (Day 1) and 1 month after second MenABCWY vaccination.

    Time frame: At Day 1 and at Day 211

  10. GMRs Against Each Serogroup B Indicator Strains at 1 Month After Second Dose of MenABCWY Vaccination

    The immune response to MenABCWY vaccine after second dose was evaluated by measuring the human serum bactericidal activity against each of the N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively) compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.

    Time frame: At Day 211 compared to baseline (Day 1)

07

Results

Posted Jul 3, 2024

Participant flow

Out of 1250 participants enrolled,3 participants did not receive vaccination as they did not meet the eligibility criteria, therefore only 1247 participants were included in the Exposed Set and started the study.

Participant flow — Overall Study
MilestoneABCWY GroupACWY Group
Started626621
Completed541542
Not completed8579
Withdrew: Adverse event58
Withdrew: Lost to follow-up4431
Withdrew: Protocol violation15
Withdrew: Withdrawal by subject2725
Withdrew: Migrated / moved from the study area88
Withdrew: Other02

Outcome measures

PrimaryPercentages of Participants With a 4-fold Rise in Human Serum Bactericidal Assay (hSBA) Titers Against N. Meningitidis Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination and the Single MenACWY Vaccination, Relative to Baseline

Four-fold rise is defined as: - a post-vaccination hSBA titer equal to or higher than (\>=) 16 for participants with a pre-vaccination hSBA titer \<4; - a post-vaccination hSBA titer \>= 4 times the LLOQ for participants with a pre vaccination hSBA titer \>= limit of detection (LOD) but \< LLOQ; and - a post-vaccination hSBA titer \>= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer \>= LLOQ.

Time frame:
At 1 month after vaccination schedule (i.e., Day 211 for ABCWY group and Day 31 for ACWY group) compared to Day 1 (Baseline)
Reported as:
Number · Percentage of Participants
Percentages of Participants With a 4-fold Rise in Human Serum Bactericidal Assay (hSBA) Titers Against N. Meningitidis Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination and the Single MenACWY Vaccination, Relative to Baseline
Percentage of ParticipantsABCWY GroupACWY Group
Meningitis A95.3 (90.89 to 97.93)95.0 (92.78 to 96.77)
Meningitis C94.5 (90.07 to 97.32)94.0 (91.62 to 95.80)
Meningitis W95.6 (91.48 to 98.07)93.9 (91.59 to 95.79)
Meningitis Y95.0 (90.72 to 97.69)94.4 (92.12 to 96.20)
Statistical analysis
  • ABCWY Group vs ACWY Group · Difference in percentage of participants: 0.2 · 0.95% CI -4.38 to 3.50
  • ABCWY Group vs ACWY Group · Difference in percentage of participants: 0.5 · 0.95% CI -4.14 to 3.98
  • ABCWY Group vs ACWY Group · Difference in percentage of participants: 1.6 · 0.95% CI -2.73 to 4.89
  • ABCWY Group vs ACWY Group · Difference in percentage of participants: 0.6 · 0.95% CI -3.93 to 3.91
PrimaryPercentages of Participants With a 4-fold Rise in hSBA Titers Against N. Meningitidis Serogroups A, C, W, and Y at 1 Month After the First MenABCWY Vaccination and the Single MenACWY Vaccination, Relative to Baseline

Four-fold rise is defined as: - a post-vaccination hSBA titer equal to or higher than (\>=) 16 for participants with a pre-vaccination hSBA titer \<4; - a post-vaccination hSBA titer \>= 4 times the LLOQ for participants with a pre vaccination hSBA titer \>= limit of detection (LOD) but \< LLOQ; and - a post-vaccination hSBA titer \>= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer \>= LLOQ.

Time frame:
At 1 month after the first vaccination (i.e., Day 31) compared to Day 1 (Baseline)
Reported as:
Number · Percentage of Participants
Percentages of Participants With a 4-fold Rise in hSBA Titers Against N. Meningitidis Serogroups A, C, W, and Y at 1 Month After the First MenABCWY Vaccination and the Single MenACWY Vaccination, Relative to Baseline
Percentage of ParticipantsABCWY GroupACWY Group
Meningitis A92.5 (89.90 to 94.66)95.0 (92.78 to 96.77)
Meningitis C94.0 (91.76 to 95.83)94.0 (91.62 to 95.80)
Meningitis W94.3 (92.10 to 96.09)93.9 (91.59 to 95.79)
Meningitis Y93.7 (91.32 to 95.51)94.4 (92.12 to 96.20)
Statistical analysis
  • ABCWY Group vs ACWY Group · Difference in percentage of participants: -2.5 · 0.95% CI -5.59 to 0.47
  • ABCWY Group vs ACWY Group · Difference in percentage of participants: 0.1 · 0.95% CI -2.76 to 2.94
  • ABCWY Group vs ACWY Group · Difference in percentage of participants: 0.4 · 0.95% CI -2.41 to 3.25
  • ABCWY Group vs ACWY Group · Difference in percentage of participants: -0.8 · 0.95% CI -3.62 to 2.09
PrimaryNumber of Participants With Solicited Administration Site Events Following Vaccination at Day 1 for ABCWY Group and ACWY Group

Assessed solicited administration site events include injection site pain, erythema, swelling, induration. Any pain = occurrence of the symptom regardless of intensity grade and any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.

Time frame:
During the 7 days (including day of vaccination) following vaccination at day 1 for ABCWY group and ACWY group
Reported as:
Count of participants · Participants
Number of Participants With Solicited Administration Site Events Following Vaccination at Day 1 for ABCWY Group and ACWY Group
ParticipantsABCWY GroupACWY Group
Injection site pain486191
Erythema299
Swelling2613
Induration2414
PrimaryNumber of Participants With Solicited Administration Site Events Following Vaccination at Day 181 for ABCWY Group

Assessed solicited administration site events include injection site pain, erythema, swelling, induration. Any pain = occurrence of the symptom regardless of intensity grade and any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.

Time frame:
During the 7 days (including day of vaccination) following vaccination at Day 181 for ABCWY group
Reported as:
Count of participants · Participants
Number of Participants With Solicited Administration Site Events Following Vaccination at Day 181 for ABCWY Group
ParticipantsABCWY Group
Injection site pain377
Erythema31
Swelling30
Induration22
PrimaryNumber of Participants With Solicited Systemic Events Following Vaccination at Day 1 for the ABCWY Group and ACWY Group

Assessed solicited systemic events include fever \[body temperature \>= 38.0°C (celsius) /100.4°F (Fahrenheit)\], nausea, fatigue, myalgia, arthralgia, headache.

Time frame:
During the 7 days (including day of vaccination) following vaccination at day 1 for the ABCWY group and ACWY group
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic Events Following Vaccination at Day 1 for the ABCWY Group and ACWY Group
ParticipantsABCWY GroupACWY Group
Fever127
Nausea8875
Fatigue244222
Myalgia9066
Arthralgia4549
Headache249208
PrimaryNumber of Participants With Solicited Systemic Events Following Vaccination at Day 181 for the ABCWY Group

Assessed solicited systemic events include fever \[body temperature \>= 38.0°C/100.4°F\], nausea, fatigue, myalgia, arthralgia, headache.

Time frame:
During the 7 days (including day of vaccination) following vaccination at day 181 for the ABCWY group
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic Events Following Vaccination at Day 181 for the ABCWY Group
ParticipantsABCWY Group
Fever9
Nausea58
Fatigue167
Myalgia67
Arthralgia30
Headache167
PrimaryNumber of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs)

Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it. An MAE is defined as an unsolicited AE for which the participant received medical attention such as hospitalization, or an emergency room visit, or visit to/by a health care provider.

Time frame:
During the 30 days (including day of vaccination) following vaccination at day 1 for ABCWY group and ACWY group
Reported as:
Count of participants · Participants
Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs)
ParticipantsABCWY GroupACWY Group
Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs)9693
PrimaryNumber of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs) Following Vaccination at Day 181 for ABCWY Group

Any AE-untoward medical occurrence in a patient/clinical investigation participant, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it.

Time frame:
During the 30 days (including day of vaccination) following vaccination at day 181 for ABCWY group
Reported as:
Count of participants · Participants
Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs) Following Vaccination at Day 181 for ABCWY Group
ParticipantsABCWY Group
Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs) Following Vaccination at Day 181 for ABCWY Group72
PrimaryNumber of Participants With SAEs, AEs Leading to Withdrawal, AESIs and Medically Attended AEs

SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were assessed throughout the study period are reported in this outcome measure.

Time frame:
From Day 1 to Day 361 (throughout the study period)
Reported as:
Count of participants · Participants
Number of Participants With SAEs, AEs Leading to Withdrawal, AESIs and Medically Attended AEs
ParticipantsABCWY GroupACWY Group
SAEs187
AEs leading to withdrawal46
AESIs04
Medically Attended AEs223206
SecondaryPercentages of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Serogroups A, C, W, and Y at Day 1, 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination

The immune response to MenABCWY vaccine after the first dose and single dose of MenACWY vaccine was evaluated by measuring the percentage of participants with hSBA titers \>= LLOQ against each of the serogroups A, C, W and Y.

Time frame:
At Day 1 (pre-vaccination) and 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group)
Reported as:
Number · Percentage of Participants
Percentages of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Serogroups A, C, W, and Y at Day 1, 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination
Percentage of ParticipantsABCWY GroupACWY Group
Meningitis A, Day 127.7 (23.94 to 31.61)28.8 (25.02 to 32.77)
Meningitis A, Day 3198.3 (96.98 to 99.20)98.1 (96.66 to 99.06)
Meningitis C, Day 157.7 (53.67 to 61.72)56.2 (52.03 to 60.23)
Meningitis C, Day 3198.9 (97.65 to 99.54)99.0 (97.81 to 99.63)
Meningitis W, Day 136.3 (32.48 to 40.35)33.4 (29.62 to 37.44)
Meningitis W, Day 3198.4 (96.99 to 99.21)96.8 (95.03 to 98.06)
Meningitis Y, Day 137.5 (33.61 to 41.51)34.9 (31.00 to 38.94)
Meningitis Y, Day 3197.9 (96.36 to 98.85)97.6 (96.06 to 98.70)
SecondaryPercentages of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination

The immune response to MenABCWY vaccine after the second dose was evaluated by measuring the percentage of participants with hSBA titers \>= LLOQ against each of the serogroups A, C, W and Y.

Time frame:
1 month after the vaccination schedule (i.e., Day 211 for ABCWY group [second dose])
Reported as:
Number · Percentage of Participants
Percentages of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination
Percentage of ParticipantsABCWY Group
Meningitis A, Day 21199.5 (97.41 to 99.99)
Meningitis C, Day 211100.0 (98.27 to 100.00)
Meningitis W, Day 211100.0 (98.28 to 100.00)
Meningitis Y, Day 211100.0 (98.26 to 100.00)
SecondaryhSBA Geometric Mean Titers (GMTs) Against Serogroups A, C, W, and Y at Day 1, 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination

The immune response to MenABCWY after first dose and single dose of MenACWY vaccine was evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their associated 2-sided 95% confidence intervals were calculated.

Time frame:
At Day 1 and 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group)
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titers (GMTs) Against Serogroups A, C, W, and Y at Day 1, 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination
TitersABCWY GroupACWY Group
Meningitis A, Day 115.30 (13.07 to 17.92)16.34 (13.96 to 19.14)
Meningitis A, Day 31670.78 (594.71 to 756.58)1282.56 (1135.84 to 1448.23)
Meningitis C, Day 131.90 (26.63 to 38.23)29.76 (24.81 to 35.71)
Meningitis C, Day 312945.68 (2471.13 to 3511.36)2552.27 (2138.66 to 3045.87)
Meningitis W, Day 112.08 (10.31 to 14.15)11.08 (9.45 to 12.99)
Meningitis W, Day 311899.60 (1638.73 to 2202.00)1665.64 (1435.57 to 1932.58)
Meningitis Y, Day 112.84 (11.16 to 14.76)11.86 (10.29 to 13.66)
Meningitis Y, Day 311590.71 (1380.78 to 1832.55)1578.42 (1369.00 to 1819.88)
SecondaryhSBA Geometric Mean Titers (GMTs) Against Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination

The immune response to MenABCWY after second dose was evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their associated 2-sided 95% confidence intervals were calculated.

Time frame:
1 month after the vaccination schedule (i.e., Day 211 for ABCWY group [second dose])
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titers (GMTs) Against Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination
TitersABCWY Group
Meningitis A, Day 211645.24 (544.11 to 765.16)
Meningitis C, Day 2112350.14 (1809.69 to 3052.00)
Meningitis W, Day 2111173.61 (940.25 to 1464.89)
Meningitis Y, Day 2111130.54 (916.85 to 1394.04)
SecondaryGeometric Mean Ratios (GMRs) Against Serogroups A, C, W, and Y at 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination

The immune response to MenABCWY vaccine after first and single dose of MenACWY vaccine are evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.

Time frame:
At 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group) compared to baseline (Day 1)
Reported as:
Geometric mean · Ratio
Geometric Mean Ratios (GMRs) Against Serogroups A, C, W, and Y at 1 Month After the First MenABCWY Vaccination and After the Single MenACWY Vaccination
RatioABCWY GroupACWY Group
Meningitis A, Day 3143.98 (36.92 to 52.40)76.91 (64.53 to 91.66)
Meningitis C, Day 3192.87 (77.13 to 111.83)86.36 (71.63 to 104.12)
Meningitis W, Day 31154.09 (125.80 to 188.73)150.83 (123.00 to 184.96)
Meningitis Y, Day 31124.11 (103.23 to 149.23)134.66 (111.75 to 162.26)
SecondaryGeometric Mean Ratios (GMRs) Against Serogroups A, C, W, and Y at 1 Month After Second MenABCWY Vaccination

The immune response to MenABCWY vaccine after second dose are evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.

Time frame:
At 1 month after the vaccination schedule (i.e., Day 211 for ABCWY group [second dose]) compared to baseline (Day 1)
Reported as:
Geometric mean · Ratio
Geometric Mean Ratios (GMRs) Against Serogroups A, C, W, and Y at 1 Month After Second MenABCWY Vaccination
RatioABCWY Group
Meningitis A, Day 21144.74 (34.67 to 57.74)
Meningitis C, Day 21168.33 (52.19 to 89.46)
Meningitis W, Day 21197.66 (72.52 to 131.52)
Meningitis Y, Day 21182.45 (62.80 to 108.24)
SecondaryPercentages of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After the Second Dose of MenABCWY Vaccination

The immune response to MenABCWY vaccine after second dose was evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively).

Time frame:
At Day 1 and at Day 211
Reported as:
Number · Percentage of Participants
Percentages of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After the Second Dose of MenABCWY Vaccination
Percentage of ParticipantsABCWY Group
fHbp (M14459) Ab, Day 18.7 (5.05 to 13.74)
fHbp (M14459) Ab, Day 21188.5 (82.60 to 92.92)
NadA (96217) Ab, Day 17.7 (4.25 to 12.50)
NadA (96217) Ab, Day 21195.8 (91.45 to 98.28)
NHBA (M13520) Ab, Day 120.2 (14.65 to 26.77)
NHBA (M13520) Ab, Day 21196.3 (92.21 to 98.65)
PorAP1.4 (NZ98/254) Ab, Day 12.7 (0.89 to 6.23)
PorAP1.4 (NZ98/254) Ab, Day 21175.6 (68.30 to 81.97)
Composite Response, Day 11.1 (0.13 to 3.93)
Composite Response, Day 21172.0 (64.41 to 78.68)
SecondaryPercentages of Participants With 4-fold Rise in hSBA Titers Against Each N. Meningitidis Serogroup B Indicator Strains at 1 Month After the Second MenABCWY Vaccination

The immune response to MenABCWY after second dose is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). compared to baseline (day 1) in terms of 4-fold rise in hSBA titers. For each of the serogroup B indicator strains, the 4-fold rise is defined as: a post-vaccination hSBA titer \>=16 for participants with a pre-vaccination hSBA titer \<4; . a post-vaccination hSBA titer \>= 4 times the LLOQ for participants with a prevaccination hSBA titer \>= limit of detection (LOD) but \< LLOQ; and, a post-vaccination hSBA titer \>= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer \>= LLOQ.

Time frame:
At Day 211 compared to baseline (Day 1)
Reported as:
Number · Percentage of Participants
Percentages of Participants With 4-fold Rise in hSBA Titers Against Each N. Meningitidis Serogroup B Indicator Strains at 1 Month After the Second MenABCWY Vaccination
Percentage of ParticipantsABCWY Group
fHbp (M14459) Ab68.1 (60.35 to 75.17)
NadA (96217) Ab90.1 (84.46 to 94.25)
NHBA (M13520) Ab64.6 (56.68 to 71.96)
PorAP1.4 (NZ98/254) Ab45.7 (37.84 to 53.68)
SecondaryGMTs Against Each Serogroup B Indicator Strains at Day 1 and at 1 Month After Second MenABCWY Vaccination

The immune response to MenABCWY vaccine after the second dose was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively) in terms of GMTs at baseline (Day 1) and 1 month after second MenABCWY vaccination.

Time frame:
At Day 1 and at Day 211
Reported as:
Geometric mean · Titers
GMTs Against Each Serogroup B Indicator Strains at Day 1 and at 1 Month After Second MenABCWY Vaccination
TitersABCWY Group
fHbp (M14459) Ab, Day 12.84 (2.53 to 3.19)
fHbp (M14459) Ab, Day 21117.56 (13.52 to 22.80)
NadA (96217) Ab, Day 18.62 (7.39 to 10.06)
NadA (96217) Ab, Day 211143.61 (106.71 to 193.26)
NHBA (M13520) Ab, Day 13.28 (2.59 to 4.15)
NHBA (M13520) Ab, Day 21124.82 (19.19 to 32.11)
PorAP1.4 (NZ98/254) Ab, Day 13.13 (2.86 to 3.43)
PorAP1.4 (NZ98/254) Ab, Day 21111.44 (8.61 to 15.19)
SecondaryGMRs Against Each Serogroup B Indicator Strains at 1 Month After Second Dose of MenABCWY Vaccination

The immune response to MenABCWY vaccine after second dose was evaluated by measuring the human serum bactericidal activity against each of the N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively) compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.

Time frame:
At Day 211 compared to baseline (Day 1)
Reported as:
Geometric mean · Ratio
GMRs Against Each Serogroup B Indicator Strains at 1 Month After Second Dose of MenABCWY Vaccination
RatioABCWY Group
fHbp (M14459) Ab6.29 (4.84 to 8.18)
NadA (96217) Ab16.67 (12.25 to 22.70)
NHBA (M13520) Ab7.69 (6.08 to 9.72)
PorAP1.4 (NZ98/254) Ab3.65 (2.76 to 4.83)

Adverse events

Collected over Solicited AEs were collected during the 7-day follow-up period after vaccination. Unsolicited AEs were collected during the 30-day follow-up period after vaccination. SAEs were collected through the entire period of the study (from Day 1 up to study end [Day 361]). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABCWY Group1/626 (0.2%)18/626 (2.9%)583/626 (93.1%)
ACWY Group1/621 (0.2%)7/621 (1.1%)552/621 (88.9%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventABCWY GroupACWY Group
Pilonidal diseaseInfections and infestations1/6262/621
AppendicitisInfections and infestations2/6260/621
Suicidal ideationPsychiatric disorders2/6260/621
Bipolar disorderPsychiatric disorders0/6261/621
Completed suicidePsychiatric disorders1/6261/621
DepressionPsychiatric disorders0/6261/621
Intentional self-injuryPsychiatric disorders0/6261/621
GastroschisisCongenital, familial and genetic disorders0/6261/621
Joint injuryInjury, poisoning and procedural complications0/6261/621
Norovirus infectionInfections and infestations1/6260/621
Most frequent other events
Showing 10 of 305
Most frequent other events
EventABCWY GroupACWY Group
Administration site painGeneral disorders524/626455/621
HeadacheNervous system disorders323/626291/621
FatigueGeneral disorders318/626293/621
MyalgiaMusculoskeletal and connective tissue disorders139/626113/621
NauseaGastrointestinal disorders132/626124/621
COVID-19Infections and infestations92/62697/621
ArthralgiaMusculoskeletal and connective tissue disorders71/62678/621
Administration site indurationGeneral disorders54/62640/621
Administration site erythemaGeneral disorders53/62630/621
Administration site swellingGeneral disorders49/62637/621

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)ABCWY GroupACWY GroupTotal
Mean17.2 ± 2.5317.2 ± 2.6317.2 ± 2.58
Sex: Female, Male
Sex: Female, Male(Participants)ABCWY GroupACWY GroupTotal
Female343324667
Male283297580
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ABCWY GroupACWY GroupTotal
Black or African American9486180
American Indian or Alaska Native112
Asian223355
Native Hawaiian or Other Pacific Islander268
White474464938
Other UNSPECIFIED333164
08

Study locations

69 sites
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
  • GSK Investigational Site
    Banning, California 92220, United States
  • GSK Investigational Site
    Chula Vista, California 91911, United States
  • GSK Investigational Site
    West Covina, California 91790, United States
  • GSK Investigational Site
    Washington, District of Columbia 20017, United States
  • GSK Investigational Site
    Miami, Florida 33126, United States
  • GSK Investigational Site
    Miami, Florida 33135, United States
  • GSK Investigational Site
    Port Orange, Florida 32127, United States
  • GSK Investigational Site
    Atlanta, Georgia 30338, United States
  • GSK Investigational Site
    Columbus, Georgia 31904, United States
  • GSK Investigational Site
    Sandy Springs, Georgia 30328, United States
  • GSK Investigational Site
    Meridian, Idaho 83642, United States
  • GSK Investigational Site
    Champaign, Illinois 61822, United States
  • GSK Investigational Site
    Quincy, Illinois 62301, United States
  • GSK Investigational Site
    Louisville, Kentucky 40291, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Fall River, Massachusetts 02725, United States
  • GSK Investigational Site
    Methuen, Massachusetts 01844, United States
  • GSK Investigational Site
    Roslindale, Massachusetts 02135, United States
  • GSK Investigational Site
    Grosse Pointe Woods, Michigan 48236, United States
  • GSK Investigational Site
    Biloxi, Mississippi 39531, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87102, United States
  • GSK Investigational Site
    Syracuse, New York 13210, United States
  • GSK Investigational Site
    Fayetteville, North Carolina 28304, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27612, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Cranberry Township, Pennsylvania 16066, United States
  • GSK Investigational Site
    Monongahela, Pennsylvania 15063, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15025, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15217, United States
  • GSK Investigational Site
    Warwick, Rhode Island 02886-6110, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406, United States
  • GSK Investigational Site
    Greenville, South Carolina 29607, United States
  • GSK Investigational Site
    Austin, Texas 78745, United States
  • GSK Investigational Site
    Beaumont, Texas 77706, United States
  • GSK Investigational Site
    Carrollton, Texas 75010, United States
  • GSK Investigational Site
    Dallas, Texas 75251, United States
  • GSK Investigational Site
    Houston, Texas 77055, United States
  • GSK Investigational Site
    Katy, Texas 77450, United States
  • GSK Investigational Site
    Longview, Texas 75605, United States
  • GSK Investigational Site
    Plano, Texas 75024, United States
  • GSK Investigational Site
    The Woodlands, Texas 77381-3527, United States
  • GSK Investigational Site
    Kaysville, Utah 84037, United States
  • GSK Investigational Site
    Layton, Utah 84041, United States
  • GSK Investigational Site
    Roy, Utah 84067, United States
  • GSK Investigational Site
    Syracuse, Utah 84075, United States
  • GSK Investigational Site
    Seattle, Washington 98105, United States
  • GSK Investigational Site
    Caba, Buenos Aires C1222, Argentina
  • GSK Investigational Site
    Ciudad Autonoma Buenos Aires, Buenos Aires C1425AWK, Argentina
  • GSK Investigational Site
    Mar del Plata, Buenos Aires B7600FYH, Argentina
  • GSK Investigational Site
    San Miguel de Tucuman, Tucumán T4000NWB, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, Tucumán T4000IHE, Argentina
  • GSK Investigational Site
    Buenos Aires, 1426, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, C1428, Argentina
  • GSK Investigational Site
    Cordoba, 5000, Argentina
  • GSK Investigational Site
    Rio Cuarto, 5800, Argentina
  • GSK Investigational Site
    Coffs Harbour, New South Wales 2450, Australia
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Kanwal, New South Wales 2259, Australia
  • GSK Investigational Site
    Maroubra, New South Wales 2035, Australia
  • GSK Investigational Site
    Taringa, Queensland 4068, Australia
  • GSK Investigational Site
    Tarragindi, Queensland 4121, Australia
  • GSK Investigational Site
    Clayton, Victoria 3168, Australia
  • GSK Investigational Site
    Parkville, Victoria 3052, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Guelph, Ontario N1H 1B1, Canada
  • GSK Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • GSK Investigational Site
    Toronto, Ontario M9V 4B4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in May 2023, 27 months.

Results were first posted in Jul 2024, 1 year 2 months after primary completion.

Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2021
First posted
Jan 13, 2021
StartActual
Jan 25, 2021
Primary completionActual
May 3, 2023
CompletionActual
Sep 29, 2023
Results first posted
Jul 3, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04707391
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 13, 2021
Start date
Jan 25, 2021
Primary completion
May 3, 2023
Completion
Sep 29, 2023
Results posted
Jul 3, 2024
Last update
Jul 3, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion